Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
- EligibilityCriteria: Inclusion Criteria:  ≥18 years of age Biopsy proven fibrillary glomerulonephritis Proteinuria > 1.0 g/24hrs prior to initiation of immunosuppressive therapy eGFR ≥ 20 ml/min/BSA  Exclusion Criteria:  Secondary FGN (due to monoclonal gammopathy, autoimmune disease or malignancy) Presence of a secondary pathology on biopsy (e.g. diabetic nephropathy) Hepatitis B, C or HIV positive Pregnant or breast-feeding Active infection Kidney transplant Anemia with Hgb < 8.0 g/dL Thrombocytopenia with platelet count < 100'000 Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complication Patients who have received cyclophosphamide in the last 6 months Patients who have received ACTH and/or mycophenolate mofetil in the last 30 days Patient who are on prednisone therapy at a dose > 10 mg/day in the last 15 days Patients who received rituximab previously with CD20 count of < 5 cells/microliter at the time of enrollment For women who are not postmenopausal (greater than or equal to [>/=] 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of less than (<) 1 percent (%) per year, during the treatment period and for at least 18 months after the last dose of study drug For men: agreement to remain abstinent or use two adequate methods for contraception, including at least one method with failure rate of less than 1% per year during the treatment period and for at least 6 months (180 days) after the last dose of drug - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult